Cellectis SA (CLLS) Earnings Date & Reports

Key Takeaways

• Cellectis S.A. (NASDAQ: CLLS) is expected to report its third-quarter 2026 results after the market close on November 13, 2026.
• Analysts, on average, project a net loss of $0.18 per share, a sharp reversal from the $0.01 per-share profit posted in the same quarter last year.
• Consensus revenue is forecast near $15.61 million, down significantly from the $37.16 million reported in Q3 2025.
• In its most recent quarter, Cellectis beat earnings-per-share (EPS) estimates while missing on the revenue line, a pattern investors will watch closely.
• Key themes heading into the print include research and development (R&D) spending, cash runway, and clinical progress for its off-the-shelf CAR-T (chimeric antigen receptor T-cell) candidates.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Cellectis is a clinical-stage biotechnology company focused on gene editing and allogeneic, or "off-the-shelf," CAR-T cell therapies for cancer. Because its products are not yet commercialized, quarterly results often swing sharply based on collaboration revenue, milestone payments, and operating costs rather than product sales. That makes the earnings release a window into the company's spending discipline and cash position. For investors, the report matters less for headline revenue and more for signals about clinical progress, funding, and whether management can extend its financial runway as development costs continue. Prior quarters have shown meaningful revenue volatility tied to partnerships, adding to the importance of guidance and commentary alongside the headline numbers.

Earnings Expectations

Wall Street consensus calls for Cellectis to report a net loss of $0.18 per share for the third quarter of 2026, according to data compiled by MarketBeat. That compares with earnings of $0.01 per share in the year-ago period. On the top line, analysts expect revenue of approximately $15.61 million, a sharp decline from $37.16 million in Q3 2025.

The company's recent reporting history has been uneven. In its most recent quarter, ended June 30, 2026, Cellectis posted a loss of $0.22 per share, narrower than the $0.26 consensus loss, while revenue of roughly $6.90 million fell short of expectations. Cellectis has beaten consensus EPS estimates in three of its last eight quarters, underscoring the volatility that often accompanies milestone-driven biotech revenue. Heading into this report, investors will be watching not only the headline EPS and revenue figures but also R&D expenses, cash and cash equivalents, and any updates to pipeline timelines.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Cellectis across the biotechnology space, it offers a structured way to surface ideas and monitor shifts in momentum. Explore the AI Screener to refine your market research.

Market Reaction and Investor Sentiment

Sentiment heading into the report appears cautious, reflecting the expected year-over-year decline in revenue and the return to a net loss. Cellectis has a history of sharp post-earnings moves, in part because milestone-heavy revenue makes results difficult to forecast. A beat or miss on the top line can matter as much as the EPS figure for a pre-revenue biotech. Key risk factors include the pace of cash burn, potential dilution from financing activities, and any setbacks or delays in clinical programs. Conversely, positive pipeline updates, new collaboration revenue, or disciplined expense management could support the stock. Investors should be prepared for above-average volatility around the announcement given the company's relatively small market capitalization and clinical-stage profile.

Forward Outlook and Key Factors to Monitor

Following the earnings report, investors will likely focus on several forward-looking items. First, cash runway remains a central concern. As a clinical-stage company, Cellectis relies on existing cash and partnership funding to advance its pipeline, so commentary on the balance sheet and any financing plans will be closely scrutinized.

Second, R&D expense trends will matter. The company's spending on clinical trials and manufacturing is a key driver of its losses, and any indication of slowing or accelerating costs can shape expectations for future quarters.

Third, pipeline progress is critical. Updates on its allogeneic CAR-T programs, including enrollment, regulatory interactions, and data readouts, are likely to carry more long-term weight than any single quarter's financials. Investors should also watch for changes in collaboration agreements, which have historically driven large swings in reported revenue.

Finally, broader sentiment toward the biotechnology sector and gene-editing companies may influence how the stock trades after the release, independent of the company's own results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations